Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance

Proteasome inhibitors have shown relevant clinical activity in several hematological malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient outcomes such as survival and quality of life, when compared with other therapies. However, initial response to the therapy is a c...

Full description

Bibliographic Details
Main Author: Leonardo-Sousa, Carlota (author)
Other Authors: Carvalho, Andreia Neves (author), Guedes, Romina A. (author), Fernandes, Pedro M. P. (author), Aniceto, Natália (author), Salvador, Jorge A. R. (author), Gama, Maria João (author), Guedes, Rita C. (author)
Format: article
Language:eng
Published: 2022
Subjects:
ubiquitin–proteasome pathway
proteasome inhibitors
mechanisms of resistance
innate resistance
acquired resistance
multiple myeloma
cancer
Adult
Bortezomib
Humans
Proteasome Endopeptidase Complex
Proteasome Inhibitors
Quality of Life
Antineoplastic Agents
Multiple Myeloma
Neoplasms
Online Access:http://hdl.handle.net/10316/103390
Country:Portugal
Oai:oai:estudogeral.sib.uc.pt:10316/103390

Internet

http://hdl.handle.net/10316/103390

Similar Items